Merck: new indication approved for Keytruda in Europe

(CercleFinance.com) - Merck announced on Thursday that the European Commission has granted marketing authorization for Keytruda, its blockbuster immunotherapy, in the treatment of operable non-small cell lung cancer at high risk of recurrence.


Brussels' approval covers, more specifically, the combination of Keytruda with chemotherapy in the neoadjuvant (pre-operative) treatment of the disease, then as monotherapy as adjuvant therapy.

Merck points out that this is the first time that an anti-PD-1/L1 therapy has been approved for the treatment of operable non-small cell lung cancer in Europe.

This is the sixth indication for Keytruda in the treatment of bronchial cancer on the Old Continent.


Copyright (c) 2024 CercleFinance.com. All rights reserved.